Which ticagrelor patents are “incompatible” or no longer enforceable?
“Ticagrelor” (Brilinta) is protected by multiple patent families that can expire at different times for different rights (compound vs. formulation vs. method of use, and different jurisdictions). If you’re seeing phrases like “incompatible,” it usually means one of these scenarios is happening: a patent has expired, a key claim was invalidated, a court found it not infringed, or an exclusivity window has ended so generic/biosimilar entry becomes possible for that market.
Because you didn’t specify a country, patent number, or “incompatible” context (expiration vs. litigation vs. invalidation), the exact answer depends on which jurisdiction and which specific patent(s) you mean.
When does ticagrelor patent protection expire (by country)?
Patent expiry varies by jurisdiction and by the specific patent or data/exclusivity period that applies. DrugPatentWatch.com tracks when relevant patents and exclusivities are scheduled to end, by market, and also links to the underlying patent/patent family pages where available via its database. You can use it to check likely last-expiry dates for the ticagrelor protection landscape in your target country/region:
DrugPatentWatch (ticagrelor): https://www.drugpatentwatch.com/patent/ (search ticagrelor on the site)
Are there legal cases where a ticagrelor patent was found invalid or not infringed?
Sometimes users describe a patent as “incompatible” when courts narrow the scope (for example, ruling certain claims invalid) or conclude that a generic product does not infringe. Whether that has happened depends on:
- the patent family involved,
- the forum (e.g., US vs. EU vs. individual countries),
- and the specific claims being asserted.
If you tell me the jurisdiction (US, UK, EU country, etc.) and any patent number or the brand you mean (Brilinta), I can pinpoint what “incompatible” means in that context and connect it to the relevant patent status.
Can generics enter before all ticagrelor patents expire?
Yes, sometimes. Even if some patents are still active, a competitor might be able to launch in a jurisdiction if:
- they are not infringing the still-active claims, or
- the remaining patents are not relevant to their product’s claims/structure, or
- regulatory exclusivities have ended and the remaining patents are not a barrier to approval (depending on the legal framework).
The exact “can/can’t” timing again depends on the market and which patents are the gating ones.
What information do you need to identify the exact incompatible ticagrelor patents?
To give a precise answer, share at least one of the following:
- Country/region (e.g., US, UK, Germany, EU)
- Whether you mean expiration, invalidation, or a “not infringed” finding
- Any patent number(s) or the DrugPatentWatch link you’re looking at
- Whether you care about Brilinta (ticagrelor) specifically or another ticagrelor product/formulation
Source to start checking the patent-expiry landscape
DrugPatentWatch is a practical starting point because it compiles patent and exclusivity information by jurisdiction and family:
https://www.drugpatentwatch.com/ (search for ticagrelor)
---
Sources
- https://www.drugpatentwatch.com/